BioSpace News Archive

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced the pricing of its upsized underwritten public offering of 4,755,000 shares of its common stock at a public offering price of $47.00 per share.

The increased efforts of pharmaceutical companies for the development of novel therapies to treat infectious diseases will positively influencing market growth.

INVO Bioscience, Inc. (NASDAQ: INVO), INVOcell®, today announced the signing of a joint venture agreement in partnership with reproductive specialist Dr. Sue Ellen Carpenter, M.D. through its wholly-owned subsidiary, INVO Centers, LLC, to open an INVO clinic in Atlanta.

Anuncia Inc., a therapeutic medical device company and an emerging leader in cerebrospinal fluid management innovation, announced it is moving its headquarters to Scottsdale, Ariz.

Method Does Not Require Antibody Conjugated Metallic Nanoparticles

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgramostim compared to placebo.

Everads Therapy, a life sciences company developing a novel and differentiated suprachoroidal delivery technology for facilitating treatment of retinal diseases, announced today that a clinical-stage gene therapy company has entered into a collaboration to evaluate suprachoroidal delivery for its gene therapy pipeline programs using Everads’ delivery platform.

Medsenic, announced today that it has entered into an exclusive licensing agreement with Australian company Phebra for the development of their patented OATO formulation (Oral Arsenic Trioxide) in the treatment of autoimmune diseases.

Scientists from The Feinstein Institutes for Medical Research today announced the publication of results from a phase 3 clinical trial looking at the safety and efficacy of the oral neuroactive steroid zuranolone (30mg) in the treatment of patients with postpartum depression (PPD).

Tomorrow is Canada Day and after months of collective efforts to reduce COVID-19 activity levels and increase first and second dose COVID-19 vaccine coverage, we can all have a sense of pride in having supported each other.